Use of early tumor shrinkage as a response to VEGF inhibitors as a predictor of progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)

被引：0
|
作者：
Gruenwald, Viktor
Seidel, Christoph
Fenner, Martin
Woike, Michael
Kalanovic, Daniel
机构：
[1] Hannover Med Sch, Dept Hematol Hemostasis Oncol & Stem Cell Transpl, Hannover, Germany
[2] Pfizer, Berlin, Germany
[3] Pfizer Pharma GmbH, Berlin, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4631
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Use of progression-free survival (PFS) to predict overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)
    Halabi, S.
    Rini, B. I.
    Stadler, W. M.
    Small, E. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] The impact of insurance status on progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)
    Castro, Daniela
    Tripathi, Nishita
    Sayegh, Nicolas
    Gebrael, Georges
    Li, Xiaochen
    Meza, Luis
    Zengin, Zeynep
    Chehrazi-Raffle, Alex
    Govindarajan, Ameish
    Dizman, Nazli
    Ebrahimi, Hedyeh
    Chawla, Neal
    Mercier, Benjamin
    Hsu, Joann
    Shi, Jessica
    Philip, Errol
    Bergerot, Cristiane
    Barragan-Carrillo, Regina
    Pal, Sumanta
    [J]. ONCOLOGIST, 2023, 28 : S5 - +
  • [3] Progression-free survival (PFS) and overall survival (OS) in patients receiving three targeted therapies (TTs) for metastatic renal cell carcinoma (mRCC)
    Verzoni, Elena
    Iacovelli, Roberto
    Rizzo, Mimma
    Felici, Alessandra
    Cascinu, Stefano
    Di Lorenzo, Giuseppe
    Cerbone, Linda
    Ortega, Cinzia
    Masini, Cristina
    Giganti, Maria Olga
    Lorusso, Vito
    Messina, Caterina
    Atzori, Francesco
    De Vincenzo, Fabio
    Sacco, Cosimo
    Boccardo, Francesco
    Valduga, Francesco
    Massari, Francesco
    Tassi, Renato
    Procopio, Giuseppe
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [4] Progression-free survival (PFS) of first-line VEGF-targeted therapy as a prognostic parameter for overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).
    Seidel, C.
    Fenner, M.
    Reuter, C. W.
    Ganser, A.
    Gruenwald, V.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] Factors impacting progression-free survival (PFS) as a predictor of overall survival (OS)
    Stewart, David J.
    Bosse, Dominick
    Hilton, John Frederick
    Goss, Glenwood D.
    Fung-Kee-Fung, Michael
    Jonker, Derek J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] PROGRESSION FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN PATIENTS RECEIVING 3 TARGETED THERAPIES (TTS) FOR METASTATIC RENAL-CELL CARCINOMA (MRCC)
    Iacovelli, R.
    Santoni, M.
    Di Lorenzo, G.
    Cerbone, L.
    Aglietta, M.
    Masini, C.
    Giganti, M. O.
    Messina, C.
    Sternberg, C. N.
    Procopio, G.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 270 - 271
  • [7] Progression free survival (PFS) and overall survival (OS) in patients receiving 3 targeted therapies (TTs) for metastatic renal-cell carcinoma (mRCC)
    Elena, V.
    Iacovelli, R.
    Santoni, M.
    Di Lorenzo, G.
    Cerbone, L.
    Ortega, C.
    Masini, C.
    Giganti, M. O.
    Messina, C.
    De Vincenzo, F.
    Procopio, G.
    [J]. BJU INTERNATIONAL, 2012, 110 : 5 - 5
  • [8] Progression-free survival (PFS) as a surrogate for overall survival (OS)
    Stewart, David J.
    Bosse, Dominick
    Hilton, John
    Goss, Glenwood
    Fung-Kee-Fung, Michael
    Jonker, Derek
    [J]. CANCER RESEARCH, 2018, 78 (13)
  • [9] Prognostic ability of early tumor shrinkage on overall survival (OS) in metastatic renal cell carcinoma (mRCC) - a validation study
    Pond, G. R.
    Dietrich, M.
    Gruenwald, V.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [10] Early onset hypothyroidism as a predictor for progression-free survival (PFS) and overall survival (OS) benefit in patients with advanced renal cell carcinoma treated with first-line sunitinib
    Pinto, Alvaro
    Garrido, Maria
    Cruz, Patricia
    Lopez, David
    Zambrana, Francisco
    Aguayo, Cristina
    Fellu, Jaime
    Espinosa, Enrique
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345